The report was based on survey responses from more than 300 U.S. pharmacies.
The average cost of Lispro for uninsured patients was $97.51 — nearly four times higher than the $25 price cap set by Eli Lilly. In addition, 42 percent of the surveyed pharmacies did not have the lower-priced generic in stock.
Eli Lilly, Sanofi and Novo Nordisk — the nation’s three largest insulin manufacturers — all announced insulin price cuts in March. While most of these price drops take effect in late 2023 and 2024, Eli Lilly rolled out a cap for Lispro this May.
Editor’s note: Becker’s has reached out to Eli Lilly for comment and will update the article as more information becomes available.
